Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of MK-0616 on Levothyroxine Pharmacokinetics
NCT06625814Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jul 2024
- Primary completion
- Aug 2024
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of enlicitide in hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoints: Area under the Concentration-Time Curve from Time 0 to 48 hours of Levothyroxine, Maximum Plasma Concentration of Levothyroxine at 48 hours and 4 more. Started Jul 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06625814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06625814.